FIND Study Shows Cepheid TB Test Performs Well in Remote Labs, Reduces Time to Treatment | GenomeWeb

By Ben Butkus

Cepheid's PCR-based test for tuberculosis and rifampicin resistance has received another clinical endorsement for its ability to perform in remote and resource-poor regions of the world, according to a research study published this week.

The positive findings were published in the same week that Cepheid reported strong first-quarter results and several financial analysts raised their earnings estimates and price targets for the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.